ArticleBMJ open2025

Protocol for a multicentre, open-label, dose-escalation phase I/II study evaluating the tolerability, safety, efficacy and pharmacokinetics of repeated continuous intravenous PPMX-T003 in patients with aggressive natural killer cell leukaemia.

Noriko Fukuhara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.